Basolateral amygdala astrocytes modulate diabetic neuropathic pain and may be a potential therapeutic target for koumine
Open Access
- 10 January 2023
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (10) , 1408-1428
Abstract
Background and Purpose: New remedies are required for the treatment of diabetic neuropathic pain (DNP) due to insufficient efficacy of available therapies. Here, we used chemogenetic approaches combined with in vivo pharmacology to elucidate the role of basolateral amygdala (BLA) astrocytes in DNP pathogenesis and provide new insights into therapeutic strategies for DNP.Experimental Approach: A streptozotocin‐induced DNP model was established. Designer receptors exclusively activated by designer drugs (DREADDs) were used to regulate astrocyte activity. Mechanical hyperalgesia was assessed using the electronic von Frey test. Anxiety‐like behaviours were detected using open field and elevated plus maze tests. Astrocytic activity was detected by immunofluorescence, and cytokine content was determined by ELISA.Key Results: BLA astrocytes were regulated by DREADDs, and inhibition of BLA astrocytes attenuated mechanical allodynia and pain‐related negative emotions in DNP rats. In contrast, temporary activation of BLA astrocytes induced allodynia without anxious behaviours in naive rats. In addition, koumine (KM) alleviated mechanical allodynia and anxiety‐like behaviours in DNP rats, inhibited the activation of BLA astrocytes and suppressed the inflammatory response. Furthermore, persistent activation of BLA astrocytes through chemogenetics mimicked chronic pain, and KM alleviated the pain hypersensitivity and anxiety‐like behaviours.Conclusion and Implications: DREADDs bidirectionally regulate the activity of BLA astrocytes, which proves for the first time the role of BLA astrocyte activation in the pathogenesis of DNP and represents a novel therapeutic strategy for DNP. KM ameliorates DNP, perhaps by inhibiting the activation of BLA astrocytes and reveal KM as a potential candidate for treating DNP.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81973309, 81701307)
This publication has 68 references indexed in Scilit:
- Basolateral Amygdala Lesion Inhibits the Development of Pain Chronicity in Neuropathic Pain RatsPLOS ONE, 2013
- The active alkaloids of Gelsemium elegans Benth. are potent anxiolyticsPsychopharmacology, 2012
- Neuron–astrocyte signaling network in spinal cord dorsal horn mediates painful neuropathy of type 2 diabetesGlia, 2012
- Effects of koumine, an alkaloid of Gelsemium elegans Benth., on inflammatory and neuropathic pain models and possible mechanism with allopregnanolonePharmacology Biochemistry and Behavior, 2012
- Preparative separation of alkaloids from Gelsemium elegans Benth. using pH-zone-refining counter-current chromatographyJournal of Chromatography A, 2011
- Spinal astrocytic activation contributes to mechanical allodynia in a mouse model of type 2 diabetesBrain Research, 2011
- Mechanisms of Neuropathic PainNeuron, 2006
- Plants with central analgesic activityPhytomedicine, 2001
- STZ Transport and Cytotoxicity: Specific Enhancement in GLUT2-Expressing CellsDiabetes, 1994
- Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic painPain, 1993